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Abstract
Background—Although only a small proportion of thin melanomas result in lymph node 
metastasis, the abundance of these lesions results in a relatively large absolute number of patients 
with a diagnosis of nodal metastases, determined by either sentinel lymph node (SLN) biopsy or 
clinical nodal recurrence (CNR).
Methods—Independent cohorts with thin melanoma and either SLN metastasis or CNR were 
identified at two melanoma referral centers. At both centers, SLN metastasis patients were 
included. At center 1, the CNR cohort included patients with initial negative clinical nodal 
evaluation followed by CNR. At center 2, the CNR cohort was restricted to those presenting in the 
era before the use of SLN biopsy. Uni- and multivariable analyses of melanoma-specific survival 
(MSS) were performed.
Results—At center 1, 427 CNR patients were compared with 91 SLN+ patients. The 5- and 10-
year survival rates in the SLN group were respectively 88 and 84 % compared with 72 and 49 % in 
the CNR group (p < 0.0001). The multivariate analysis showed age older than 50 years (hazard 
ratio [HR] 1.5; 95 % confidence interval [CI] 1.2–1.9), present ulceration (HR 1.9; 95 % CI 1.2–
2.9), unknown ulceration (HR 1.6; 95 % CI 1.3–2.1), truncal site (HR 1.6; 95 % CI 1.2–2.2), and 
CNR (HR 3.3; 95 % CI 1.8–6.0) to be associated significantly with decreased MSS (p < 0.01 for 
each). The center 2 cohort demonstrated remarkably similar findings, with a 5-year MSS of 88 % 
in the SLN (n = 29) group and 76 % in the CNR group (n = 39, p = 0.09).
Conclusion—Patients with nodal metastases from thin melanomas have a substantial risk of 
melanoma death. This risk is lower among patients whose disease is discovered by SLN biopsy 
rather than CNR.
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The incidence of melanoma has increased dramatically in recent decades, and much of that 
increase has occurred among patients with thin primary tumors. These lesions are generally 
low risk with good to excellent long-term melanoma-specific survival (MSS).1,2 However, it 
is well known that a minority of these patients (< 5 %) will have tumor spread to regional 
lymph nodes, and the 10-year melanoma-specific and overall survival rates for this cohort 
range from approximately 4.5–8 %.3–7
Although the group of patients with nodal metastases represents a relatively small proportion 
of the population, the abundance of thin melanomas (nearly 70 % of newly diagnosed 
lesions) results in a substantial absolute number of patients who fall into the nodal 
metastasis group.5 This group is difficult to study, and as a result, recommendations for 
treatment of thin melanoma have been challenging.6–8
Our two melanoma referral centers have large prospectively maintained clinical databases 
and were early users of the sentinel lymph node (SLN) biopsy technique. This technique not 
only allows identification of a relatively large number of SLN-positive patients, but also 
provides a follow-up period long enough to identify patients with nodal metastases who did 
not undergo SLN biopsy but rather had nodal disease discovered through CNR, which can 
present after a long interval in patients with thin melanomas.
We analyzed these groups of nodal metastasis patients to compare features of patients with 
metastases discovered through SLN biopsy with those of CNR patients. We also compared 
the outcomes of those groups. Because the analysis was retrospective, we examined data 
from the two participating centers separately in an effort to determine the reproducibility of 
the findings.
For thin melanomas, the frequency of nodal involvement is relatively low.9,10 As a result, it 
would be very difficult to demonstrate a survival advantage in a prospective randomized 
trial. Nodal surgery would not be expected to carry therapeutic value if pathologically 
nonmalignant lymph nodes are removed, so any benefit that might be present for those 
patients who harbor lymph node metastases would be diluted by the vast majority of patients 
who did not have such disease. Conducting a trial of sufficient size to identify a statistically 
significant survival difference is not practical. Moreover, the moderate morbidity of 
complete lymph node dissection (LND) would be difficult to justify, even from the 
standpoint of regional control of disease, for a population in which 95 % of the patients have 
lymph nodes uninvolved with metastatic disease.11
Although the best criteria for selecting patients with thin melanoma for SLN biopsy remains 
an area of active research, several studies have confirmed the prognostic significance of SLN 
metastases, even for these generally low-risk lesions.11–18 Similar to patients with thick 
melanomas, for whom SLN biopsy can be performed with minimal morbidity and appears to 
carry important, independent prognostic information, patients with thin melanoma can 
undergo SLN biopsy with similar low procedural risks and potential of prognostic value for 
selected patients.19–22 The prognosis for patients with thin melanomas and nodal metastases 
detected by SLN biopsy compared with the prognosis for those with this condition detected 
clinically is less well defined.
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The John Wayne Cancer Institute (JWCI) and the University of Pennsylvania’s Pigmented 
Lesion Group (Penn) have prospectively maintained melanoma clinical databases for several 
decades. These databases were queried for patients who had a diagnosis of melanomas with 
a thickness of 1 mm or more but had no clinical evidence of lymph node metastases.
For this analysis, we identified patients with lymph node metastases detected either by SLN 
biopsy or at the time of clinical nodal recurrence (CNR). The SLN biopsy technique and 
pathologic assessment were performed as previously described.3,23 Completion LND was 
routinely recommended for patients with a positive SLN, and completion LND was 
performed for the majority (69 % JWCI, 83 % Penn). For the inguinal sites, this typically 
entailed a superficial groin dissection. For patients with CNR at inguinal sites, therapeutic 
lymphadenectomy was performed with either superficial or radical groin dissection 
depending on the extent of disease noted clinically and radiographically and on surgeon 
discretion. The study received approval from the institutional review boards (IRBs) of both 
institutions.
The characteristics of the two cohorts were examined including demographic characteristics 
(sex, age) and primary tumor characteristics (Breslow thickness, Clark level, ulceration, 
body site). The number of the Penn patients with available information regarding mitotic 
rate, tumor-infiltrating lymphocytes (TIL), regression, lymphovascular invasion (LVI), 
microsatellites, and T stage also was sufficient for analysis. Patients with false-negative SLN 
biopsies were excluded from analyses but were considered as a group separately.
The decision for SLN biopsy was ultimately left to the discretion of the surgeon and likely 
varied over time as more robust data became available regarding predictors of SLN positivity 
in thin melanoma. In addition to thickness, factors such as vertical growth phase, 
mitogenicity, ulceration, younger age, lymphovascular invasion, elevated Clark level (4 or 
5), and positive deep margin may have contributed to decision making, particularly earlier in 
the experience.
Characteristics of the SLN and CNR groups were compared. Survival time was measured 
from the date of definitive treatment for the primary melanoma in both the SLN and CNR 
groups.
The JWCI cohort was subjected to uni- and multivariate survival analyses using Kaplan–
Meier plots, log-rank testing, and Cox proportional hazard models. Unknown ulceration and 
Clark level groups were excluded from these analyses. Using variables identified as 
significant in the multivariate analysis, adjusted survival curves were plotted to examine the 
independent effect of early nodal treatment. To address issues related to bias in the SLN and 
CNR groups, pairs of patients with SLN metastases or CNR were matched using the 
significant prognostic variables, and survival analyses of these matched groups were 
performed.
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The demographic and pathologic characteristics of the SLN-positive and CNR patients in the 
Penn cohort also were compared. Survival analyses of these patients were performed to 
determine whether they were congruent with the JWCI outcomes.
RESULTS
Patient Characteristics and Demographics
The demographic and pathologic characteristics of the JWCI and Penn cohorts are provided 
in Tables 1 and 2, respectively. The JWCI SLN-positive group was older than the CNR 
group (mean age, 45 years for CNR vs 48.9 years) and had a higher proportion of Clark 
levels 4 and 5 lesions. In addition, more patients in the CNR group had unknown ulceration 
status, whereas the rate of ulceration among patients with known ulceration status was 
similar between the two groups. Breslow thickness was similar between the groups, although 
when thickness was analyzed as a continuous variable, the SLN-positive group had slightly 
thicker lesions (0.77 vs. 0.73 mm; p = 0.11). The median time to the development of nodal 
recurrence in the CNR group was 34.2 months.
The Penn cohort had a greater proportion of Clark levels 4 and 5 primary tumors and a 
greater proportion of mitogenic primary tumors in the SLN group than in the CNR group. In 
contrast to the JWCI patients, there was a higher proportion of “unknown” ulceration 
patients and a lower proportion of “present” ulceration patients in the SLN category than in 
the CNR group. The SLN-positive patients more frequently had tumors with a Breslow 
thickness of 0.76 mm or more (p = 0.047). The SLN-positive patients also differed from the 
CNR patients with regard to LVI and TIL. The overall rate of SLN positivity in the Penn 
cohort was 3.7 %. The median time to the development of CNR was 3.7 years.
Prognostic Factors for Survival
For the JWCI cohort, older age, axial anatomic site, ulceration, and presentation status of 
nodal metastasis (CNR vs. SLN biopsy) all were associated with decreased MSS (Table 3) in 
the univariate analysis. These factors all remained significantly associated with MSS (Table 
3) in the multivariate analysis. With unknown ulceration status excluded, the same variables 
remained significant in the multivariate analysis (data not shown).
The MSS rates for the SLN-positive patients compared with the CNR patients were 
respectively 88 and 72 % at 5-years and 84 and 49 % at 10 years (p < 0.0001, log-rank) (Fig. 
1). The median follow-up period for the surviving patients was 87.4 months. After matching 
using covariates identified as significant by multivariate analysis (age, ulceration status, and 
anatomic site) in 88 patient pairs, nodal disease identified by SLN biopsy was associated 
with significantly improved survival compared with CNR disease (Fig. 2).
Among the factors also available in the JWCI cohort, two factors in the Penn cohort also 
were significantly associated with decreased MSS, namely, male sex (hazard ratio [HR] 4.5; 
95 % confidence interval [CI] 1.5–13.2) and axial site (HR 3.6; 95 % CI 1.2–10.3). Given 
the small sample size, a multivariate analysis was not performed for this cohort. The 
estimated HR suggested better survival in the SLN-positive group than in the CNR group of 
a magnitude similar to that of the JWCI cohort (HR 2.3; 95 % CI 0.9–6.2; p = 0.10). The 
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median follow-up period was 6.3 years in the SLN group and 11.7 years in the CNR group. 
The survival curves were similar in the two independent center cohorts (Fig. 3).
False-Negative SLN Biopsy Patients
During the follow-up period, 17 patients in the JWCI cohort and 5 patients in the Penn 
cohort experienced regional nodal recurrence after SLN biopsy in that nodal basin (false-
negative SLN biopsy patients). The 5-year MSS rates in the respective centers were 66.7 and 
60 %. When false-negative patients were included in the SLN biopsy group of the JWCI 
patients, MSS differed significantly between the SLN and CNR groups (p < 0.0001).
DISCUSSION
Nodal metastasis occurs in patients with thin melanomas, as does death from melanoma. 
Although this is well known and well described, the relative infrequency of nodal spread in 
this group makes the phenomenon difficult to study. For example, a randomized trial 
examining the therapeutic effect of SLN biopsy in this population would be impractical due 
to the need for thousands of subjects to achieve acceptable statistical power, and such a trial 
is very unlikely ever to be conducted.
However, the sheer number of patients who will receive a diagnosis of thin melanoma make 
examination of this population quite important. If only 3 % of the patients with thin 
melanoma have nodal metastases, but approximately 70 % of newly diagnosed melanomas 
are T1, the United States would have more than 1500 patients with thin melanoma nodal 
metastases each year. It is therefore important to examine this group in detail to identify 
important prognostic factors and help guide treatment decisions.
Our study examined a large collective cohort of patients with thin melanomas and nodal 
metastases with the benefit of long-term follow-up assessment. Several significant 
prognostic factors were identified including patient age, primary tumor site, and ulceration 
status. The strongest factor, however, was the method for diagnosing the metastasis, with 
disease diagnosed by clinical recurrence showing a threefold greater risk for melanoma 
death than disease diagnosed by SLN biopsy. This raises the suggestion that early diagnosis 
of such metastases would have a beneficial effect on the clinical course of the patients. This 
is perhaps a noteworthy finding considering the limitations of this study, including 
variability in the sample sizes between the two institutions as well as in the pathologic 
variables available for analysis.
This suggestion is intuitive in many ways because patients with nodal metastases from thin 
melanomas may be the most likely to benefit from early removal of that disease because 
they are least likely to have concomitant distant dissemination of their melanoma, which 
would render nodal surgery moot.24 This also is insinuated by the results of the Multicenter 
Selective Lymphadenectomy Trial (MSLT-1), which demonstrated apparently diminishing 
survival advantages for patients undergoing SLN biopsy with increasing tumor thickness.25
The rationale for excluding patients with thin melanomas from earlier elective lymph node 
dissection trials was not lack of a biologic rationale, but rather lack of statistical power and 
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the need to subject excessive numbers of patients to complete nodal dissection in order to 
potentially benefit a few. Sentinel node biopsy avoids the need for more morbid complete 
dissections and makes consideration of nodal evaluation in thin melanoma possible.
However, any suggestion of a therapeutic effect from early nodal treatment for these patients 
certainly cannot be proved by the current analysis. It clearly is possible that our 
nonrandomized analysis was biased by factors other than nodal management that resulted in 
the observed survival difference. Indeed, the two groups differed. Many of the differences 
likely resulted from selection of high-risk patients to undergo SLN biopsy, for example, 
increased Clark’s level, mitoses, and lymphovascular invasion in the SLN biopsy group. 
Other differences such as younger age in the SLN biopsy group may have resulted from less 
aggressive treatment for older patients or perhaps biology. We have attempted to account for 
such bias.
Other known and measured prognostic variables were included in a multivariable analysis, 
and the substantial impact on outcome was retained. Pairs of patients matched for known 
prognostic variables were identified, and the survival of those with early nodal surgery was 
substantially superior to the survival of patients with similar characteristics but managed 
with nodal observation. Finally two independent populations of patients were examined at 
two institutions, and almost identical outcomes were observed. It may be difficult to identify 
a more useful data set for examination of this question.
An alternative hypothesis is that the melanoma metastases seen in the SLN were not 
clinically significant and would not progress to recurrent disease if observed. This 
hypothesis, however, is not supported by comparisons of the rates of nodal involvement for 
thin melanoma diagnosed by SLN biopsy, which after control for tumor thickness are similar 
to those seen clinically with nodal observation. In addition, multiple large series reporting 
outcomes for patients with thin melanomas undergoing SLN biopsy show nodal recurrence 
rates lower than 1 % after negative SLN biopsy, again suggesting that the nodal disease 
identified by the procedure was real.
Our analysis should not be interpreted as an endorsement for routine SLN biopsy for all 
patients with a diagnosis of thin primary melanomas. It is clear that many patients, 
particularly those with very thin tumors, can have their regional nodes safely observed. 
Current National Comprehensive Cancer Network (NCCN) Guidelines recommend 
discussion and offering of SLN biopsy to patients with thin primary melanomas 0.76 to 1 
mm in thickness with either ulceration or a mitotic rate of 1 or more per mm2. However, 
precise criteria for selecting patients with thin melanoma whose risk is high enough to 
justify SLN biopsy overall still remain controversial, with no features consistently supported 
in the literature. The current analysis does not settle that question, but we think it may 
increase the urgency for developing selection algorithms that will help to identify the 
subgroups of our patients who should or should not have the procedure.
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Melanoma-specific survival among sentinel lymph node (SLN)-positive patients compared 
with clinical nodal recurrence (CNR) at John Wayne Cancer Institute (JWCI). The survival 
of the SLN-positive patients (blue) was 88 % at 5 years and 84 % at 10 years. The survival 
of the CNR (yellow) patients was 72 % at 5 years and 49 % at 10 years
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Melanoma-specific survival in a matched cohort of sentinel lymph node (SLN)-positive 
(blue) and clinical nodal recurrence (CNR) patients (yellow) at John Wayne Cancer Institute 
(JWCI) after matching for age, anatomic site, and ulceration status
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Melanoma-specific survival among sentinel lymph node (SLN)-positive patients compared 
with clinical nodal recurrence (CNR) at John Wayne Cancer Institute (JWCI) and 
Pennsylvania’s Pigmented Lesion Group (Penn). The SLN-positive patients at JWCI (solid 
red) and Penn (dashed red). The CNR patients at JWCI (solid blue) and Penn (dashed blue)
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TABLE 1









  Female 44 (40) 38 (160) 0.255
  Male 56 (51) 62 (266)
Age (years)
  ≤50 47 (43) 67 (285) <0.001
  >50 53 (48) 33 (141)
Primary site
  Axial 69 (63) 67 (286) 0.699
  Extremity 31 (28) 33 (140)
Breslow (mm)
  ≤0.75 44 (40) 47 (202) 0.548
  >0.75 56 (51) 53 (224)
Clark level
  1–3 55 (50) 78 (334) <0.001
  4–5 40 (36) 15 (63)
  Unknown 5 (5) 7 (29)
Ulceration
  Absent 84 (76) 64 (274) <0.001
  Present 10 (9) 7 (29)
  Unknown 7 (6) 29 (123)
SLN sentinel lymph node
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TABLE 2









  Male 59 (17) 58 (21) 0.82
  Female 41 (12) 42 (15)
Age (years)
  ≤50 62 (18) 75 (27) 0.26
  >50 38 (11) 25 (9)
Primary site
  Axial 48 (14) 72 (26) 0.07
  Extremity 52 (15) 28 (10)
Breslow (mm)
  0.01–0.75 28 (8) 53 (19) 0.047
  ≥0.76 72 (21) 47 (17)
Clark level
  2–3 24 (7) 75 (27) <0.001
  4–5 72 (21) 25 (9)
  Unknown 3 (1) 0 (0)
Ulceration
  Absent 79 (23) 83 (30) 0.009
  Present 0 (0) 14 (5)
  Unknown 21 (6) 3 (1)
Mitoses
  Absent 7 (2) 25 (9) 0.029
  Present 83 (24) 75 (27)
  Unknown 10 (3) 0 (0)
TIL
  Absent 24 (7) 53 (19) 0.016
  Present 66 (19) 47 (17)
  Unknown 10 (3) 0 (0)
Regression
  Absent 72 (21) 69 (25) 0.57
  Present 14 (4) 22 (8)
  Unknown 14 (4) 8 (3)
LVI
  Absent 69 (20) 94 (34) 0.013
  Present 7 (2) 0 (0)
  Unknown 24 (7) 6 (2)
Microsatellites
  Absent 86 (25) 97 (35) 0.227





















  Present 7 (2) 0 (0)
  Unknown 7 (2) 3 (1)
Tumor stage
  T1a 7 (2) 22 (8) 0.045
  T1b 83 (24) 78 (28)
  Unknown 10 (3) 0 (0)
SLN sentinel lymph node, TIL tumor-infiltrating lymphocytes, LVI lymphovascular invasion
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